<?xml version="1.0" encoding="UTF-8"?>
<p>In the last two decades, more than 500 crystal structure of CDKs were released in the protein data bank
 <xref rid="CIT0026" ref-type="bibr">
  <sup>26</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0027" ref-type="bibr">
  <sup>27</sup>
 </xref>. Among these, a large number of CDK-2 crystal structures bound to inhibitors of diverse chemical scaffolds were reported
 <xref rid="CIT0027" ref-type="bibr">
  <sup>27</sup>
 </xref>. The use of the 
 <italic>in silico</italic> studies (virtual screening, docking studies and molecular dynamics) in the discovery and identification of new potent CDKs inhibitors was previously discussed in several reports
 <xref rid="CIT0028" ref-type="bibr">
  <sup>28–30</sup>
 </xref>. Among these techniques, virtual screening was used in several studies to design/identify novel CDK-2 inhibitors
 <xref rid="CIT0031" ref-type="bibr">
  <sup>31</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0032" ref-type="bibr">
  <sup>32</sup>
 </xref>. Poulsen et al. reported a nitrogen-linked macrocyclic CDK-2 inhibitor using structure-based design and docking studies
 <xref rid="CIT0033" ref-type="bibr">
  <sup>33</sup>
 </xref>.
</p>
